
CLAIMS

1. A solid dispersion comprising compound A:



(**A**),

or a pharmaceutically acceptable salt or solvate thereof, and a stabiliser selected from at least one of Hypromellose (HPMC) and Hypromellose acetate succinate (HPMC-AS) at a ratio of 1:1 to less than 1:3 by weight, with the proviso that the ratio is not 1:2 by weight.

2. The solid dispersion according to claim 1, wherein compound A and the stabiliser selected from at least one of Hypromellose (HPMC) and Hypromellose acetate succinate (HPMC-AS) are present at a ratio of at a ratio of 1:1 to less than 1:2 by weight.

3. The solid dispersion according to claim 1 or 2, wherein compound A and the stabiliser selected from at least one of Hypromellose (HPMC) and Hypromellose acetate succinate (HPMC-AS) are present at a ratio of 1:1 to 1:1.5 by weight.

4. The solid dispersion according to any one of claims 1 to 3, wherein compound A is in amorphous form.

5. The solid dispersion according to any one of claims 1 to 4, wherein compound A is in amorphous base form.

6. The solid dispersion according to any one of claims 1 to 5, wherein the stabiliser is HPMC.

7. The solid dispersion according to any one of claims 1 to 5, wherein the stabiliser is HPMC-AS.

8. The solid dispersion according to any one of claims 1 to 7, wherein the solid dispersion is a solid solution.

9. A solid oral dosage form, comprising a solid dispersion as claimed in any one of claims 1 to 8.

10. The solid oral dosage form according to claim 9, wherein the solid oral dosage form is a tablet.

11. A process for preparing an oral dosage form according to claim 10, comprising the steps of:

- providing a spray-dried powder by preparing a solution of the compound with the stabiliser and spray drying the solution to form a spray dried powder;
- mixing the spray-dried powder with part of tablet excipients;
- performing dry granulation of the mixture;
- adding part of tablet excipients to the granulate and mixing until homogeneous;
- compressing the mixture to provide the oral dosage form, said oral dosage form then being optionally film-coated;

or alternatively, comprising the steps of:

- providing a spray-dried powder by preparing a solution of the compound with the stabiliser and spray drying the solution to form a spray dried powder;
- mixing the spray-dried powder with tablet excipients; and
- compressing the mixture to provide the oral dosage form, said oral dosage form then being optionally film-coated.

12. An oral dosage form as claimed in claim 9 or 10, for use as a medicament.

13. An oral dosage form as claimed in claim 9 or 10, for use in the treatment of HBV infection.

14. A product containing (a) the oral dosage form as claimed in claim 9 or 10, and (b) another HBV inhibitor, in particular, a nucleoside analogue, as a combined preparation for simultaneous, separate or sequential use in the treatment of HBV infections.

15. Use of an oral dosage form as claimed in any claim 9 or 10, in the manufacture of a medicament for the treatment of HBV infection.

16. Use of a product containing (a) the oral dosage form as claimed in claim 9 or 10, and (b) another HBV inhibitor, in particular, a nucleoside analogue, in the manufacture of a combined preparation for the simultaneous, separate or sequential treatment of HBV infections.